Lilly to Invest $6 Billion in Alabama Facility for Active Pharmaceutical Ingredient Production Eli Lilly and Company today announced plans to invest more than $6 billion in a new manufacturing facility in Huntsville, Alabama. This next-generation synthetic medicine active pharmaceutical ingredient (API) facility, the…
Global health leaders convene at the IAEA headquarters in Vienna this week to advance radiation safety in medicine The International Conference on Radiation Protection in Medicine: X Ray Vision, organized by the IAEA and co-sponsored by the World Health Organization (WHO)…
Roche Highlights Lunsumio Data Demonstrating Promise in Earlier Treatment Settings for Both Indolent and Aggressive Lymphomas Roche announced today new data highlighting the potential of Lunsumio® (mosunetuzumab) in earlier treatment lines for people living with different types of lymphoma, presented…
Most Nations Advance Toward Universal Health Coverage, Yet Significant Obstacles Persist, Finds WHO–World Bank Report Since 2000, most countries – across all income levels and regions – have made concurrent progress in expanding health service coverage and reducing the financial…
Advancing Transplant Innovation with First-of-Its-Kind Insights from Organ Donor-Derived Bone Marrow Ossium Health, a bioengineering company that developed a first-of-its-kind bank of bone marrow available on-demand, will present new clinical data at the at the 66th American Society of Hematology…
Egypt Achieves Historic Milestone in Healthcare Sovereignty: Becomes Sixth Nation to Attain Plasma Self-Sufficiency with Grifols Partnership Plasma-derived medicines—a feat made possible through a groundbreaking five-year strategic alliance with Grifols, S.A. the global leader in plasma-derived therapies and healthcare innovation.…
Bristol Myers Squibb’s Breyanzi Becomes First and Only CAR T Cell Therapy Approved by FDA for Relapsed or Refractory Marginal Zone Lymphoma Breyanzi® CD19-directed chimeric antigen receptor (CAR) T cell therapy—for the treatment of adult patients with relapsed or refractory…
Cipla and Stempeutics Forge Landmark Partnership to Introduce India’s First Allogeneic Stem Cell Therapy for Knee Osteoarthritis Cipla Limited a global pharmaceutical leader with a legacy of patient-centric innovation—has officially launched Ciplostem, a groundbreaking allogeneic mesenchymal stromal cell (MSC) therapy…
Alnylam Pharmaceuticals Announces Strategic Refresh of Board of Directors to Propel Next Phase of Growth Alnylam Pharmaceuticals, Inc.the global pioneer and leader in RNA interference (RNAi) therapeutics, today announced a significant strategic evolution of its Board of Directors, reflecting the…
BioNTech Secures Overwhelming Shareholder Support, Meets Minimum Condition to Complete CureVac Exchange Offer BioNTech SE announced today that it has successfully met the minimum tender condition for its exchange offer for all outstanding shares of CureVac N.V. According to official…
ICON Survey Exposes Escalating Delays in Clinical Trial Startups—Calls for Human-Centred Site Activation Solutions biotechnology, artificial intelligence, and precision medicine, the clinical trial landscape should be accelerating. Yet, a new industry survey fromICON plc (NASDAQ: ICLR)—a global leader in clinical…
Zoetis Unveils Strategic Vision for the Future of Animal Health at Innovation Webcast, Highlighting Robust R&D Pipeline and Multi-Billion-Dollar Growth Opportunities Zoetis Inc. the global leader in animal health, hosted a highly anticipated Innovation Webcast on December 3, 2025, at…
